Does the media favor NTLA or BEAM?

In the previous week, Beam Therapeutics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 13 mentions for Beam Therapeutics and 12 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.88 beat Beam Therapeutics' score of 0.58 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NTLA or CRSP?

In the previous week, Intellia Therapeutics had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 12 mentions for Intellia Therapeutics and 10 mentions for CRISPR Therapeutics. Intellia Therapeutics' average media sentiment score of 0.88 beat CRISPR Therapeutics' score of 0.75 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NTLA or NUVL?

In the previous week, Intellia Therapeutics had 2 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Intellia Therapeutics and 10 mentions for Nuvalent. Intellia Therapeutics' average media sentiment score of 0.88 beat Nuvalent's score of 0.70 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KYMR or NTLA?

In the previous week, Intellia Therapeutics had 5 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Intellia Therapeutics and 7 mentions for Kymera Therapeutics. Intellia Therapeutics' average media sentiment score of 0.88 beat Kymera Therapeutics' score of 0.45 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Intellia Therapeutics (NTLA) Competitors

$13.30 +0.28 (+2.15%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$13.50 +0.20 (+1.50%)

As of 04:58 AM Eastern

Compare

NTLA vs. BEAM, CRSP, EDIT, NUVL, and KYMR

Should you buy Intellia Therapeutics stock or one of its competitors? MarketBeat compares Intellia Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Nuvalent (NUVL), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Intellia Therapeutics compare to Beam Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Intellia Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	27.46	-$412.69M	-$3.54	N/A
Beam Therapeutics	$139.74M	22.74	-$79.99M	-$0.68	N/A

Intellia Therapeutics currently has a consensus price target of $20.67, indicating a potential upside of 55.44%. Beam Therapeutics has a consensus price target of $46.85, indicating a potential upside of 51.65%. Given Intellia Therapeutics' higher possible upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Beam Therapeutics has a net margin of -39.66% compared to Intellia Therapeutics' net margin of -597.04%. Beam Therapeutics' return on equity of -29.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

In the previous week, Beam Therapeutics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 13 mentions for Beam Therapeutics and 12 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.88 beat Beam Therapeutics' score of 0.58 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Intellia Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	27.46	-$412.69M	-$3.54	N/A
CRISPR Therapeutics	$3.51M	1,386.57	-$581.60M	-$6.22	N/A

In the previous week, Intellia Therapeutics had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 12 mentions for Intellia Therapeutics and 10 mentions for CRISPR Therapeutics. Intellia Therapeutics' average media sentiment score of 0.88 beat CRISPR Therapeutics' score of 0.75 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

Intellia Therapeutics has a net margin of -597.04% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Intellia Therapeutics currently has a consensus target price of $20.67, suggesting a potential upside of 55.44%. CRISPR Therapeutics has a consensus target price of $67.78, suggesting a potential upside of 34.32%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Intellia Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Editas Medicine?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	27.46	-$412.69M	-$3.54	N/A
Editas Medicine	$40.52M	7.64	-$160.06M	-$1.23	N/A

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Intellia Therapeutics currently has a consensus price target of $20.67, indicating a potential upside of 55.44%. Editas Medicine has a consensus price target of $5.40, indicating a potential upside of 70.89%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Editas Medicine has a net margin of -281.59% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, Intellia Therapeutics had 11 more articles in the media than Editas Medicine. MarketBeat recorded 12 mentions for Intellia Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.94 beat Intellia Therapeutics' score of 0.88 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
Intellia Therapeutics	Positive
Editas Medicine	Positive

Intellia Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

Summary

Intellia Therapeutics beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does Intellia Therapeutics compare to Nuvalent?

Intellia Therapeutics (NASDAQ:NTLA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Intellia Therapeutics presently has a consensus target price of $20.67, suggesting a potential upside of 55.44%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Given Intellia Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Nuvalent has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Nuvalent's return on equity of -40.11% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Nuvalent	N/A	-40.11%	-35.43%

Intellia Therapeutics has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	27.46	-$412.69M	-$3.54	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Intellia Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

In the previous week, Intellia Therapeutics had 2 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Intellia Therapeutics and 10 mentions for Nuvalent. Intellia Therapeutics' average media sentiment score of 0.88 beat Nuvalent's score of 0.70 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Intellia Therapeutics beats Nuvalent on 11 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

In the previous week, Intellia Therapeutics had 5 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Intellia Therapeutics and 7 mentions for Kymera Therapeutics. Intellia Therapeutics' average media sentiment score of 0.88 beat Kymera Therapeutics' score of 0.45 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	235.14	-$311.35M	-$3.57	N/A
Intellia Therapeutics	$67.67M	27.46	-$412.69M	-$3.54	N/A

88.8% of Intellia Therapeutics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kymera Therapeutics has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Kymera Therapeutics currently has a consensus price target of $121.73, indicating a potential upside of 8.61%. Intellia Therapeutics has a consensus price target of $20.67, indicating a potential upside of 55.44%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Intellia Therapeutics has a net margin of -597.04% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Summary

Intellia Therapeutics beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Intellia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTLA vs. The Competition

Export

Metric	Intellia Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.82B	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-3.76	20.98	27.01	24.38
Price / Sales	27.46	311.10	521.33	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	2.29	8.54	10.95	6.33
Net Income	-$412.69M	$23.83M	$3.59B	$331.02M
7 Day Performance	-21.02%	-2.77%	-1.45%	-0.33%
1 Month Performance	-10.86%	5.85%	2.78%	-1.29%
1 Year Performance	15.85%	52.15%	28.53%	21.30%

Intellia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTLA Intellia Therapeutics	3.3289 of 5 stars	$13.30 +2.2%	$20.67 +55.4%	+11.3%	$1.82B	$67.67M	N/A	600	Gap Up
BEAM Beam Therapeutics	3.3869 of 5 stars	$35.32 +1.5%	$46.83 +32.6%	+45.9%	$3.63B	$164.01M	N/A	510
CRSP CRISPR Therapeutics	3.6035 of 5 stars	$61.89 +3.0%	$67.78 +9.5%	-10.6%	$5.97B	$3.51M	N/A	460	Positive News
EDIT Editas Medicine	2.5254 of 5 stars	$3.65 flat	$5.40 +47.9%	+10.9%	$357.37M	$40.52M	N/A	230
NUVL Nuvalent	2.3036 of 5 stars	$123.72 0.0%	$127.73 +3.2%	+46.5%	$9.77B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTLA) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, NUVL, and KYMR

How does Intellia Therapeutics compare to Beam Therapeutics?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Summary

How does Intellia Therapeutics compare to Nuvalent?

Summary

How does Intellia Therapeutics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, NUVL, and KYMR

How does Intellia Therapeutics compare to Beam Therapeutics?

Which has more volatility and risk, NTLA or BEAM?

Which has preferable earnings & valuation, NTLA or BEAM?

Do analysts prefer NTLA or BEAM?

Do institutionals and insiders have more ownership in NTLA or BEAM?

Is NTLA or BEAM more profitable?

Does the media favor NTLA or BEAM?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Do institutionals & insiders have more ownership in NTLA or CRSP?

Which has better earnings & valuation, NTLA or CRSP?

Does the media refer more to NTLA or CRSP?

Which has more risk and volatility, NTLA or CRSP?

Is NTLA or CRSP more profitable?

Do analysts rate NTLA or CRSP?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Which has stronger earnings & valuation, NTLA or EDIT?

Do institutionals and insiders have more ownership in NTLA or EDIT?

Do analysts recommend NTLA or EDIT?

Is NTLA or EDIT more profitable?

Does the media favor NTLA or EDIT?

Which has more risk & volatility, NTLA or EDIT?

Summary

How does Intellia Therapeutics compare to Nuvalent?

Do analysts prefer NTLA or NUVL?

Is NTLA or NUVL more profitable?

Which has higher earnings & valuation, NTLA or NUVL?

Which has more volatility and risk, NTLA or NUVL?

Does the media favor NTLA or NUVL?

Do insiders and institutionals have more ownership in NTLA or NUVL?

Summary

How does Intellia Therapeutics compare to Kymera Therapeutics?

Does the media prefer KYMR or NTLA?

Which has higher valuation and earnings, KYMR or NTLA?

Do insiders and institutionals believe in KYMR or NTLA?

Which has more risk & volatility, KYMR or NTLA?

Do analysts recommend KYMR or NTLA?

Is KYMR or NTLA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools